Ran Anbar

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Ran Anbar sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting 1 completed upper half by trial count

Ran Anbar: 1 sponsored US clinical trial, none currently recruiting.

Ran Anbar sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. The most-studied condition in this pipeline is Asthma in Children, with 1 trials.

Mid-pack sponsor footprint

Ran Anbar is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

COMPLETED

Do Bonding Disruptions Occur More Often in Children With Asthma Than in Non-asthmatic Populations?

NCT02158338

Therapeutic Areas

Asthma in Children 1
Anxiety 1

How the Ran Anbar archive is shaped

1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Asthma in Children (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ran Anbar: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ran Anbar sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Ran Anbar1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Ran Anbar sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ran Anbar sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ran Anbar page

1 registered trials is a research-attention snapshot, not an endorsement of Ran Anbar or any single study.

  • None of Ran Anbar's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Asthma in Children is the condition Ran Anbar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma in Children trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ran Anbar pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.